620. IDENTIFICATION OF BLOOD BIOMARKERS OF PSILOCYBIN-ASSISTED THERAPY TREATMENT RESPONSE FOR GENERALISED ANXIETY DISORDER
No abstract is available for this record.
Bibliographic context
- Journal
- Unknown
- Date
- 2025-07-31
- Source
- Europe PMC
- DOI
- Unavailable
- PubMed
- Unavailable
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.
Related papers
Psychedelics, entactogens and psychoplastogens for depression and related disorders.British journal of pharmacology · 2026-06-30Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized TrialClinicalTrials.gov · 2026-06-14The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy AdultsClinicalTrials.gov · 2026-06-01Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner ViolenceClinicalTrials.gov · 2026-05-13Low doses of psilocybin as adjunct pharmacological treatment to virtual reality exposure therapy for social anxiety disorder: A study protocol for a double-blind randomized controlled trial.PsyArXiv · 2026-05-13The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.ClinicalTrials.gov · 2026-05-07Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-08-31Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventionsJournal of Psychedelic Studies · 2026-07-02